The ongoing federal government shutdown has led to significant disruptions across U.S. science agencies, notably halting new grant awards from NIH and NSF and suspending various research programs. Concerns mount over layoffs and operational slowdowns within critical biomedical fields, threatening scientific progress and workforce stability. Despite uncertainties on shutdown duration and mitigation, the scientific community braces for consequences that could impair biomedical innovation and delay patient access to emerging therapies.